Skip to main content

InforMax CEO and President to Step Down

SAN FRANCISCO, Oct. 17 – InforMax today announced major changes in its leadership, including CEO Alexander Titomirov leaving his post and president and COO James Bernstein retiring.

Both executives are company founders.

Titomirov will step down as CEO upon hiring of a new CEO, according to the company. The recruiting company Heidrick & Struggles has been hired to recruit the new executive, which the company hopes to do by the first quarter 2002. Titomirov will remain chairman of the board of directors.

Bernstein will retire as president, COO, and a member of the board as of December 31, 2001, according to the company. John Green, currently executive vice president and chief financial officer of the Bethesda, Md.-based bioinformatics company, has assumed the duties of COO.

Earlier in the week, InforMax slashed its third-quarter revenue forecast and indicated that its losses for the period would be greater than expected as a result of purchasing delays triggered by a downturn in the overall economy. 

InforMax, which has a cash balance of $65 million, earlier in the week said that it expected to reach profitability by the fourth quarter of next year. 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.